## Supporting information

## Surface Chemistry Mediates the Tumor Entrance of Nanoparticles Probed by Single-Molecule Dual-Imaging Nanodots

Huiming Ren,<sup>a</sup> Qiuhui Hu,<sup>a,b</sup> Yuji Sun,<sup>a</sup> Xiaoxuan Zhou,<sup>b</sup> Yincong Zhu,<sup>a</sup> Qiuyang Dong,<sup>a</sup> Linying Chen,<sup>a</sup> Jianbin Tang,<sup>a</sup> Hongjie Hu,<sup>b</sup> Youqing Shen<sup>a</sup> and Zhuxian Zhou<sup>a,\*</sup>

<sup>a</sup>Key Laboratory of Biomass Chemical Engineering of Ministry of Education and Zhejiang Key Laboratory of Smart Biomaterials, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China

<sup>b</sup>Department of Radiology, Sir Run Run Shaw Hospital (SRRSH) of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310027, China

\*Correspondence: zhouzx@zju.edu.cn

1. Supp	plemental Figures and Tables
Scheme	<b>S1.</b> Synthesis procedure of <b>PDI-16Fmoc-G2.5</b>
Scheme	<b>S2</b> . Synthesis procedure of <b>PDI-16DOTA(tBu)-G3</b>
Scheme	<b>S3.</b> Synthesis procedure of <b>G6-Ac</b> 5
Figure S	<b>1.</b> <sup>1</sup> H NMR spectrum of Fmoc-Lys-Boc-OPFP in CDCl <sub>3</sub> 5
Figure S	<b>2.</b> <sup>1</sup> H NMR spectrum of PDI-16Fmoc-G2.5 in DMSO-d <sub>6</sub> 6
Figure S	<b>3.</b> <sup>1</sup> H NMR spectrum of Fmoc-Lys-Fmoc-OPFP in CDCl <sub>3</sub> 6
Figure S	<b>4.</b> <sup>1</sup> H NMR spectra of PDI-16DOTA(tBu)-Gn ( $n = 3-6$ ) in DMSO-d <sub>6</sub> 7
Figure S	5. MALDI-TOF mass spectrum of PDI-16DOTA(tBu)-G37
Figure S scattering	<b>6.</b> Hydrodynamic size distribution of Gn-Ac (n = 4-6) measured by dynamic light g (DLS)
Figure S phosphot	7. TEM image of G6-Ac positively stained with 2% aqueous sodium rungstate. ×120 k, 80 kV, scale bar = 100 nm
Figure S	<b>8.</b> The comparison of the zeta potential between dendrimer with and without Gd8
Figure S	<b>9.</b> Plots of $1/T_1$ versus the concentration of the contrast agents at 3T
Figure S cells of th	<b>10.</b> The dorsal whole-body fluorescence imaging of mice with 4T1 breast cancer he PDI-16(DOTA-Gd) PLL dendrimers
Figure S the PDI-1	<b>11.</b> The abdomen fluorescence imaging of the mice with 4T1 breast cancer cells of 16(DOTA-Gd) PLL dendrimers10
Figure S tumor be Gd/kg. M (d)	<b>12. (a)</b> The whole body T1-weighted MR images of mice bearing 4T1 orthotopic fore (pre) and after post-injection of ProHance®, G6-Ac and G6-OEG, at 0.1 mmol-IRI signals enhancement ratio (ER = Spost /Spre) of artery (b), kidneys (c) and liver
Figure S of the nan nanodots fresh med	<b>13</b> . (a) The experimental procedure for determining the cellular take and exocytosis nodots on 4T1 cells. (b) The flow cytometry of 4T1 cells treated with different (10 $\mu$ M) for 24 h. (c) The flow cytometry of 4T1 cells with nanodots exocytosed in dium for another 24 h
<b>Figure S</b> 4T1 cells	<b>14.</b> Confocal laser scanning microscopy (CLSM) images and the cellular uptake of after 12 h incubation with 20 $\mu$ M of the nanoprobes (Scale bar = 15 $\mu$ m)
Table S1	. Molecular weights of PDI-DOTA PLL dendrimers determined by Maldi-Tof12
Table S2	2. Molecular weights of PDI-DOTA PLL dendrimers determined by GPC12
Table S3	<b>3.</b> The parameters of the linear fitting in <b>Figure S6</b> 13

## 1. Supplemental Figures and Tables



Scheme S1. Synthesis procedure of PDI-16Fmoc-G2.5.



Scheme S2. Synthesis procedure of PDI-16DOTA(tBu)-G3.



PDI-16(DOTA-Gd)-G6-Ac (G6-Ac)

Scheme S3. Synthesis procedure of G6-Ac.



Figure S1. <sup>1</sup>H NMR spectrum of Fmoc-Lys-Boc-OPFP in CDCl<sub>3</sub>.



Figure S2. <sup>1</sup>H NMR spectrum of PDI-16Fmoc-G2.5 in DMSO-d<sub>6</sub>.



Figure S3. <sup>1</sup>H NMR spectrum of Fmoc-Lys-Fmoc-OPFP in CDCl<sub>3</sub>.



Figure S4. <sup>1</sup>H NMR spectra of PDI-16DOTA(tBu)-Gn (n = 3-6) in DMSO-d<sub>6</sub>.



Figure S5. MALDI-TOF mass spectrum of PDI-16DOTA(tBu)-G3.



**Figure S6.** Hydrodynamic size distribution of Gn-Ac (n = 4-6) measured by dynamic light scattering (DLS).



**Figure S7.** TEM image of G6-Ac positively stained with 2% aqueous sodium phosphotungstate.  $\times$ 120 k, 80 kV, scale bar = 100 nm.



Figure S8. The comparison of the zeta potential between dendrimer with and without Gd.



**Figure S9.** Plots of  $1/T_1$  versus the concentration of the contrast agents at 3T.



**Figure S10.** The dorsal whole-body fluorescence imaging of mice with 4T1 breast cancer cells of the PDI-16(DOTA-Gd) PLL dendrimers.



**Figure S11.** The abdomen fluorescence imaging of the mice with 4T1 breast cancer cells of the PDI-16(DOTA-Gd) PLL dendrimers.



**Figure S12. (a)** The whole body T1-weighted MR images of mice bearing 4T1 orthotopic tumor before (pre) and after post-injection of ProHance®, G6-Ac and G6-OEG, at 0.1 mmol-Gd/kg. MRI signals enhancement ratio (ER = Spost /Spre) of artery (b), kidneys (c) and liver (d).



**Figure S13**. (a) The experimental procedure for determining the cellular take and exocytosis of the nanodots on 4T1 cells. (b) The flow cytometry of 4T1 cells treated with different nanodots (10  $\mu$ M) for 24 h. (c) The flow cytometry of 4T1 cells with nanodots exocytosed in fresh medium for another 24 h.



**Figure S14.** Confocal laser scanning microscopy (CLSM) images and the cellular uptake of 4T1 cells after 12 h incubation with 20  $\mu$ M of the nanoprobes (Scale bar = 15  $\mu$ m).

Sample	Number of Amines	Theoretical value	Measured by Maldi-Tof	
PDI-G2	16	2790.14	2790.71	
PDI-16Fmoc-G2.5	16	8390.34	4842.71*	
PDI-16DOTA(tBu)-G3	16	13707.13	13707.15	
PDI-16DOTA(tBu)-G4	32	15756.65	15757.74	
PDI-16DOTA(tBu)-G5	64	19864.69	ND	
PDI-16DOTA(tBu)-G6	128	28062.77	ND	

Table S1. Molecular weights of PDI-DOTA PLL dendrimers determined by Maldi-Tof.

 Table S2. Molecular weights of PDI-DOTA PLL dendrimers determined by GPC.

Sample	Number of Lysine	Theoretical value	Measured by GPC	PDIs(Mw/Mn)
PDI-G1.5	12	4390	17810	1.09
PDI-16(Fmoc-Boc)-G2.5	28	9991	30390	1.06
PDI-16DOTA(tBu)-G2.5	28	17260	37010	1.08
PDI-16DOTA(tBu)-G3.5	44	22859	38220	1.09
PDI-16DOTA(tBu)-G4.5	76	34059	49910	1.12
PDI-16DOTA(tBu)-G5.5	140	56459	64560	1.14

Samula	$y = a + b^*x$				
Sample	Y-intercept (a)	Slope (b)	Pearson's R	$R^2$ (COD)	
ProHance®	$0.50\pm0.05$	$4.43\pm0.16$	0.99805	0.9961	
G4-Ac	$0.43\pm0.22$	$27.96\pm0.66$	0.99916	0.99832	
G5-Ac	$0.21\pm0.49$	$30.65 \pm 1.48$	0.99653	0.99308	
G6-Ac	$0.27\pm0.12$	$39.31\pm0.35$	0.99988	0.99976	
G6-OEG	$0.07\pm0.12$	$27.77\pm0.36$	0.99975	0.99949	

## Table S3. The parameters of the linear fitting in Figure S6.